Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2018

Study Completion Date

December 31, 2024

Conditions
Contrast Induced Nephropathy
Interventions
DEVICE

RenalGuard Therapy

Induced Diuresis with matched replacement

DRUG

Standard Therapy

Standard of care for patients at risk of CIN

Trial Locations (30)

10016

NYU Medical Center, New York

10029

Mount Sinai Medical Center, New York

10032

Columbia University, New York

10467

Montefiore Medical Center, New York

11794

Stony Brook University Medical Center, Stony Brook

15213

University of Pittsburgh, Pittsburgh

18840

Guthrie Medical Center, Sayre

20010

Washington Hospital Center, Washington D.C.

21218

Johns Hopkins University, Baltimore

27607

Rex Hospital, Raleigh

32209

University of Florida, Jacksonville

33756

Clearwater Cardiovascular, Clearwater

35924

University of Alabama, Birmingham

38801

North Mississippi Medical Center, Tupelo

49770

Northern Michigan Hospital, Petoskey

55407

Abbott Northwestern, Minneapolis

60515

Advocate Good Samaritan, Downers Grove

60611

Northwestern Memorial Hospital, Chicago

63301

St. Joseph Medical Center, Saint Charles

65040

Advocate Health, Naperville

74006

St. John Research Institute, Bartlesville

75093

Baylor Scott & White, Plano

78681

Austin Heart Round Rock, Round Rock

78756

Austin Heart Central, Austin

90505

Torrance Medical Center, Torrance

02135

St. Elizabeth's Hospital, Brighton

02601

Cape Cod Healthcare, Hyannis

01655

University of Massachusetts, Worcester

02903

Rhode Island Hospital, Providence

02906

The Miriam Hospital, Providence

Sponsors
All Listed Sponsors
lead

CardioRenal Systems, Inc.

INDUSTRY